Position in NVCT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$216,174
New position
Shares Held
11,755
first reported quarter
Ownership
0.036%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#45
of 82 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Schonfeld Strategic Advisors LLC holds $420,669,608 across 133 Biotechnology names. NVCT ranks #100 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INBX |
Inhibrx Biosciences, Inc.
|
697,586 | $66,096,273 | |
| 2 | AGIO |
Agios Pharmaceuticals, Inc.
|
520,083 | $19,300,280 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
77,272 | $18,620,233 | |
| 4 | VRDN |
Viridian Therapeutics, Inc.\DE
|
793,508 | $14,576,741 | |
| 5 | MBX |
MBX Biosciences, Inc.
|
248,670 | $13,726,584 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
227,330 | $13,721,638 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
147,425 | $12,025,457 | |
| 8 | INSM |
INSMED Inc
|
104,378 | $11,128,782 |
All Filings in NVCT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $216,174 | 11,755 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||